LENZ THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LENZ THERAPEUTICS, INC. (LENZ) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.47M, a 57.19% increase year-over-year.
- LENZ THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.32M, a 69.04% increase year-over-year.
- LENZ THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.47M, a 58.33% increase year-over-year.
- LENZ THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.85M, a 78.15% increase year-over-year.
- LENZ THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.55M, a 97.12% increase from fiscal 2024.
- LENZ THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.37M, a 373.94% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.34M, a 90.08% decline from fiscal 2022.
- LENZ THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $13.53M, a 71.95% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.47M 10-Q · filed 2026-08-11 | $8.79M derived: sum of 2 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $4.32M 10-Q · filed 2026-08-11 | |||||
| 2025-12-31 | $12.55M 10-K · filed 2026-03-24 | |||||
| 2025-09-30 | $3.47M 10-Q · filed 2025-11-05 | $6.31M derived: sum of 2 quarters · filed 2026-08-11 | $8.87M derived: sum of 3 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $2.85M 10-Q · filed 2026-08-11 | $5.40M derived: sum of 2 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $2.56M 10-Q · filed 2026-08-11 | |||||
| 2024-12-31 | $6.37M 10-K · filed 2026-03-24 | |||||
| 2024-09-30 | $2.19M 10-Q · filed 2025-11-05 | $3.79M derived: sum of 2 quarters · filed 2025-11-05 | $4.74M derived: sum of 3 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $1.60M 10-Q · filed 2025-11-05 | $2.54M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | $947.00K 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $1.34M 10-K · filed 2025-03-19 | $10.57M 10-K · filed 2024-02-27 | ||||
| 2023-09-30 | $494.00K 10-Q · filed 2024-11-06 | $2.16M 10-Q · filed 2023-11-13 | $683.00K derived: sum of 2 quarters · filed 2024-11-06 | $825.00K derived: sum of 3 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $189.00K 10-Q · filed 2024-11-06 | $2.85M 10-Q · filed 2023-08-14 | $331.00K derived: sum of 2 quarters · filed 2024-11-06 | |||
| 2023-03-31 | $142.00K 10-Q · filed 2024-11-06 | $3.26M 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $13.53M 10-K · filed 2024-02-27 | |||||
| 2022-09-30 | $3.21M 10-Q · filed 2023-11-13 | $6.57M derived: sum of 2 quarters · filed 2023-11-13 | $9.91M derived: sum of 3 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $3.36M 10-Q · filed 2023-11-13 | $6.70M derived: sum of 2 quarters · filed 2023-11-13 | ||||
| 2022-03-31 | $3.34M 10-Q · filed 2023-11-13 | |||||
| 2021-12-31 | $7.87M 10-K · filed 2023-03-20 | |||||
| 2021-09-30 | $2.37M 10-Q · filed 2022-11-09 | $4.39M derived: sum of 2 quarters · filed 2022-11-09 | $5.42M derived: sum of 3 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $2.02M 10-Q · filed 2022-11-09 | $3.05M derived: sum of 2 quarters · filed 2022-11-09 | ||||
| 2021-03-31 | $1.03M 10-Q · filed 2022-11-09 | |||||
| 2020-12-31 | $177.00K 10-K · filed 2022-03-21 | |||||
| 2020-09-30 | $36.00K 10-Q · filed 2021-11-10 | $37.00K derived: sum of 2 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $1.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |